Open Access and Peer-reviewed
Home Journal Issues Guide for Authors Editorial Board Aims & Scope About Journal News & Announcements


Review Article 


Advances in Kinase Inhibitors Anticancers: Highlights and Challenges

Ali N. Hussein, Zahraa Albasry.

Abstract
Protein tyrosine kinase (PTK) is considered as one of the main signaling catalysts during the transduction of cell signal. The role of PTK is to transfer the ATP-γ-phosphate to the tyrosine moiety in the targeted protein. This, in turn, resulted in many cellular processes, including; phosphorylation, controlling cell growth, regulation of the cell differentiation, apoptosis and many other cellular processes. Accordingly, any faulty expression of PTK however, resulted in faulty cell multiplication. Nowadays, various PTKs are utilized as targets for the treatment of cancer.
The mechanism by which the tyrosine kinase inhibitors (TKIs) act as antitumor can be simplified as the TKIs prevent the ATP from reaching its binding site by competitory mechanism. This in turn will inhibit the phosphorylation of tyrosine kinase leading to suppress the tumor cell proliferation. TKIs have gained a great attention by researchers leading to discover many successful therapies, nevertheless, there are always challenges to be tackled.
In this work, the authors summarize the mechanism of TKIs, highlighted the successes and drawbacks of TKIs for anticancer therapies.

Key words: Antitumor, Tyrosine kinase inhibitors, Protein tyrosine kinase.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Ali N. Hussein
Articles by Zahraa Albasry
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Hussein AN, Albasry Z. Advances in Kinase Inhibitors Anticancers: Highlights and Challenges. doi:https://doi.org/10.31838/ejmcm.07.02.02


Web Style

Hussein AN, Albasry Z. Advances in Kinase Inhibitors Anticancers: Highlights and Challenges. http://www.ejmcm.com/?mno=130232 [Access: October 13, 2020]. doi:https://doi.org/10.31838/ejmcm.07.02.02


AMA (American Medical Association) Style

Hussein AN, Albasry Z. Advances in Kinase Inhibitors Anticancers: Highlights and Challenges. doi:https://doi.org/10.31838/ejmcm.07.02.02



Vancouver/ICMJE Style

Hussein AN, Albasry Z. Advances in Kinase Inhibitors Anticancers: Highlights and Challenges. doi:https://doi.org/10.31838/ejmcm.07.02.02



Harvard Style

Hussein, A. N. & Albasry, . Z. (2020) Advances in Kinase Inhibitors Anticancers: Highlights and Challenges. doi:https://doi.org/10.31838/ejmcm.07.02.02



Turabian Style

Hussein, Ali N., and Zahraa Albasry. 2020. Advances in Kinase Inhibitors Anticancers: Highlights and Challenges. doi:https://doi.org/10.31838/ejmcm.07.02.02



Chicago Style

Hussein, Ali N., and Zahraa Albasry. "Advances in Kinase Inhibitors Anticancers: Highlights and Challenges." doi:https://doi.org/10.31838/ejmcm.07.02.02



MLA (The Modern Language Association) Style

Hussein, Ali N., and Zahraa Albasry. "Advances in Kinase Inhibitors Anticancers: Highlights and Challenges." doi:https://doi.org/10.31838/ejmcm.07.02.02



APA (American Psychological Association) Style

Hussein, A. N. & Albasry, . Z. (2020) Advances in Kinase Inhibitors Anticancers: Highlights and Challenges. doi:https://doi.org/10.31838/ejmcm.07.02.02








AUTHOR LOGIN

REVIEWER LOGIN

Indexed
&
Abstracted


Journal is indexed by the following services:

Scopus
CrossRef
JISC KB+
SHERPA RoMEO
Cengage Learning
Directory of Open Access Journals (DOAJ)
Google Scholar

In addition, all journals are available for harvesting via OAI-PMH.


ABOUT JOURNAL
POLICIES
STATEMENTS

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.

The articles in European Journal of Molecular & Clinical Medicine are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.